↓ Cooling
Business
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology drug portfolio.
3 trends tracked about this subject — the full history, oldest to newest below.
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology drug portfolio.
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics, marking the pharmaceutical company's largest deal since 2019.
Pharmaceutical giant AbbVie is reportedly closing in on an $11 billion deal to acquire biotech firm Apogee Therapeutics.